Measurement of cellular β-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems

被引:7
作者
Volbracht, Christiane [2 ]
Penzkofer, Stephan [1 ]
Mansson, David [2 ]
Christensen, Kenneth Vielsted [2 ]
Fog, Karina [2 ]
Schildknecht, Stefan [1 ]
Leist, Marcel [1 ]
Nielsen, Jacob [2 ]
机构
[1] Univ Konstanz, Dept Biol, D-78457 Constance, Germany
[2] H Lundbeck & Co AS, DK-2500 Copenhagen, Denmark
关键词
BACE1; Amyloid-beta peptide (A beta); APP; SEAP; CGC; HEK293; AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE INHIBITOR; STRUCTURE-BASED DESIGN; ALZHEIMERS-DISEASE; GENE-EXPRESSION; IN-VIVO; PEPTIDE PRODUCTION; BACE-1; INHIBITORS; KNOCKOUT MICE; CLEAVAGE;
D O I
10.1016/j.ab.2009.01.008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Amyloid-beta peptide (A beta), a putatively causative agent of Alzheimer's disease (AD), is proteolytically derived from beta-amyloid precursor protein (APP). Here we describe cellular assays to detect the activity of the key protease beta-site of APP cleaving enzyme 1 (BACE1) based on an artificial reporter construct containing the BACE1 cleavage site of APP. These methods allow identification of inhibitors and indirect modulators of BACE1. In primary neuronal cultures transfected with human APP constructs (huAPP), A beta production was modified by BACE1 inhibitors similarly to the production of endogenous murine A beta in wild-type cells and to that of different transgenic neurons. To further improve the assay, we substituted the extracellular domain of APP by secreted alkaline phosphatase (SEAP). SEAP was easily quantified in the cell culture supernatants after cleavage of SEAP-APP by BACE1 or alpha-secretases. To render the assay specific for BACE1, the alpha-secretase cleavage site of SEAP-APP was eliminated either by site-directed Mutagenesis or by substituting the transmembrane part of APP by the membrane domain of the erythropoietin receptor (EpoR). The pharmacology of these constructs was characterized in detail in HEK293 cells (human embryonic kidney cell line), and the SEAP-APP-EpoR construct was also introduced into primary murine neurons and there allowed specific measurement of BACE1 activity. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:208 / 220
页数:13
相关论文
共 66 条
[11]   Aspartic peptidase inhibitors: Implications in drug development [J].
Dash, C ;
Kulkarni, A ;
Dunn, B ;
Rao, M .
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 38 (02) :89-119
[12]   Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice [J].
Dominguez, D ;
Tournoy, J ;
Hartmann, D ;
Huth, T ;
Cryns, K ;
Deforce, S ;
Serneels, L ;
Camacho, IE ;
Marjaux, E ;
Craessaerts, K ;
Roebroek, AJM ;
Schwake, M ;
D'Hooge, R ;
Bach, P ;
Kalinke, U ;
Moechars, D ;
Alzheimer, C ;
Reiss, K ;
Saftig, P ;
De Strooper, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) :30797-30806
[13]   Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain [J].
Dovey, HF ;
John, V ;
Anderson, JP ;
Chen, LZ ;
Andrieu, PD ;
Fang, LY ;
Freedman, SB ;
Folmer, B ;
Goldbach, E ;
Holsztynska, EJ ;
Hu, KL ;
Johnson-Wood, KL ;
Kennedy, SL ;
Kholedenko, D ;
Knops, JE ;
Latimer, LH ;
Lee, M ;
Liao, Z ;
Lieberburg, IM ;
Motter, RN ;
Mutter, LC ;
Nietz, J ;
Quinn, KP ;
Sacchi, KL ;
Seubert, PA ;
Shopp, GM ;
Thorsett, ED ;
Tung, JS ;
Wu, J ;
Yang, S ;
Yin, CT ;
Schenk, DB ;
May, PC ;
Altstiel, LD ;
Bender, MH ;
Boggs, LN ;
Britton, TC ;
Clemens, JC ;
Czilli, DL ;
Dieckman-McGinty, DK ;
Droste, JJ ;
Fuson, KS ;
Gitter, BD ;
Hyslop, PA ;
Johnstone, EM ;
Li, WY ;
Little, SP ;
Mabry, TE ;
Miller, FD ;
Ni, B .
JOURNAL OF NEUROCHEMISTRY, 2001, 76 (01) :173-181
[14]   Presenilin and nicastrin regulate each other and determine amyloid β-peptide production via complex formation [J].
Edbauer, D ;
Winkler, E ;
Haass, C ;
Steiner, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) :8666-8671
[15]   CLEAVAGE OF AMYLOID-BETA PEPTIDE DURING CONSTITUTIVE PROCESSING OF ITS PRECURSOR [J].
ESCH, FS ;
KEIM, PS ;
BEATTIE, EC ;
BLACHER, RW ;
CULWELL, AR ;
OLTERSDORF, T ;
MCCLURE, D ;
WARD, PJ .
SCIENCE, 1990, 248 (4959) :1122-1124
[16]   α-secretase activation -: An approach to Alzheimer's disease therapy [J].
Fahrenholz, Falk ;
Postina, Rolf .
NEURODEGENERATIVE DISEASES, 2006, 3 (4-5) :255-261
[17]   Modification of a PCR-based site-directed mutagenesis method [J].
Fisher, CL ;
Pei, GK .
BIOTECHNIQUES, 1997, 23 (04) :570-&
[18]   β-secretase as a therapeutic target for inhibitor drugs [J].
Ghosh, AK ;
Hong, L ;
Tang, J .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (11) :1135-1144
[19]   Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor [J].
Gitter, BD ;
Czilli, DL ;
Li, WY ;
Dieckman, DK ;
Bender, MH ;
Nissen, JS ;
Mabry, TE ;
Yin, TG ;
Boggs, LN ;
McClure, DB ;
Little, SP ;
Johnstone, EM ;
Audia, JE ;
May, PC ;
Hyslop, PA .
NEUROBIOLOGY OF AGING, 2004, 25 :S571-S571
[20]  
HAASS C, 1994, J BIOL CHEM, V269, P17741